Concord Biotech Moat Analysis: Score & Risks
Concord Biotech Ltd.
A first-pass moat teardown of Concord Biotech Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.
First-pass narrow-to-wide read — primary edge in Cost Advantage. Provisional, single-pass evidence.
Concord Biotech Ltd. scores 5.51 on MoatSCORE 6.0 — a narrow-to-wide moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.
Seven dimensions of moat
Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.
“Our strong product portfolio leverages niche expertise and backward integration for Key Starting Materials (KSMs), ensuring efficiency and quality.”
“This expansion aligns with our R&D priorities, where we are developing niche products with complex processes and limited competition.”
“We supply formulations primarily in India through government and corporate hospitals, while in the US and emerging markets in Asia, Africa, and Latin America, we rely on distributor collaborations.”
“We have a dedicated intellectual property team responsible for filing patents in both the Indian and overseas markets.”
“The factors mentioned above were largely beyond our control and were not related to lower demand, loss of market share or pricing pressure.”
“our customers have begun the qualification process for the Limbasi facility, allowing us to serve them from this unit as well”
D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.
The barrier gate — first-pass
Effective barrier 6 — at or above 6, consistent with a narrow-to-wide read. First-pass estimate.
Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.
Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.
Where this note fits. This company is one of 509 Indian companies we have scored for moat durability — 370 narrow, 126 narrow-trending-wide, none wide. Every score, dimension by dimension, is free in the Moat Screener.
Member discussion